The Nitrosamine “Saga”: Lessons Learned from Five Years of Scrutiny
Raphael Nudelman(Teva Pharmaceuticals (Israel)), Anne-Laure Werner(Unknown), Bruno Mouton(Merck KGaA, Darmstadt (Germany)), Joerg Schlingemann(Merck KGaA, Darmstadt (Germany)), Grace Kocks, David J. Ponting(University of Leeds), Stéphanie Simon(Merck KGaA, Darmstadt (Germany)), Andrew Teasdale(AstraZeneca (United Kingdom)), G. Smith(AstraZeneca (United Kingdom))
Cited by 78
Related Papers
OxyR
|Cell|2002|474
S-nitrosylation: spectrum and specificity
|Nature Cell Biology|2001|243
Drug Insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis
|Nature Clinical Practice Rheumatology|2008|197
An Integrated in Silico 3D Model-Driven Discovery of a Novel, Potent, and Selective Amidosulfonamide 5-HT<sub>1A</sub> Agonist (PRX-00023) for the Treatment of Anxiety and Depression
|Journal of Medicinal Chemistry|2006|141
A nitric oxide processing defect of red blood cells created by hypoxia: Deficiency of S-nitrosohemoglobin in pulmonary hypertension
|Proceedings of the National Academy of Sciences|2005|132